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Evidence for successive peptide binding and quality control
stages during MHC class I assembly
Jonathan W. Lewis and Tim Elliott
Intracellular antigens are continually presented to
cytotoxic T lymphocytes by major histocompatibility
complex (MHC) class I molecules, which consist of a
polymorphic 43 kDa heavy chain and a 12 kDa soluble
subunit b2-microglobulin (b2m), and which bind an 8–10
amino-acid antigenic peptide. The assembly of this
trimolecular complex takes place in the lumen of the
endoplasmic reticulum (ER) [1] and almost certainly
requires cofactors. Most MHC class I molecules in the
ER that have not yet acquired peptide are
simultaneously bound to the transporter associated
with antigen processing (TAP), to the 48 kDa
glycoprotein tapasin and to the lectin-like chaperone
calreticulin, in a multicomponent ‘loading complex’ [2].
Previous studies have shown that a mutant MHC class I
molecule T134K (in which Thr134 was changed to Lys)
fails to bind to TAP [3]. Here, we show that this point
mutation also disrupted, directly or indirectly, the
interaction between MHC class I molecules and
calreticulin. T134K molecules did not present viral
antigens to T cells even though they bound peptide and
b2m normally in vitro. They exited the ER rapidly as
‘empty’ MHC class I complexes, unlike empty wild-type
molecules which are retained in the ER and degraded.
We show here that, paradoxically, the rapid exit of
empty T134K molecules from the ER was dependent on
a TAP-derived supply of peptides. This implies that
MHC class I assembly is a two-stage process: initial
binding of suboptimal peptides is followed by peptide
optimisation that depends on temporary ER retention.
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Results and discussion
In addition to the failure of T134K molecules to interact
with the TAP1–TAP2 heterodimer, Figure 1a shows that
they did not associate with the ER-resident protein cal-
reticulin either. Both human leukocyte antigens (HLAs)
HLA-A*0201 and HLA-Cw4 could be recovered by coim-
munoprecipitation with both anti-TAP2 and anti-calretic-
ulin antibodies in digitonin lysates, but no association with
T134K was detected. T134K did, however, interact with
the ER chaperone calnexin — a protein that is homolo-
gous to calreticulin — in the β2m-negative cell line Daudi
(Figure 1b). These experiments demonstrate that whereas
calreticulin can discriminate between the wild-type
HLA-A*0201 and the T134K mutant, calnexin cannot.
The basis for this discrimination is unclear: both calretic-
ulin and calnexin are reported to have very similar, if not
identical, substrate specificities and have been shown to
bind preferentially to monoglucosylated trimming inter-
mediates of glycoproteins in the ER ([4,5], reviewed in
[6,7]). Consistent with this, the interaction between cal-
nexin and HLA-A*0201 or T134K is sensitive to cas-
tanospermine, a compound that inhibits the trimming of
the immature glycan on the heavy chain by glucosidase I
and II (Figure 1b). Figure 1c shows that castanospermine
also inhibits the interaction between HLA-A*0201 and
calreticulin in a dose-dependent way. Given that Thr134
is at a position distal to the single glycosylation site
(Asn86) of human MHC class I molecules, as seen in the
three-dimensional structure [8], these results suggest that,
in addition to the glycan-dependent aspect of calreticulin
binding to MHC class I molecules, other aspects con-
tribute to this interaction. 
The failure of T134K to interact with calreticulin could be
due to the direct disruption of the calreticulin-binding site
on the class I heavy chain, or could be an indirect effect via
the disruption of an interaction with TAP, tapasin or some
other cofactor. It is possible, for example, that the interac-
tion between MHC class I and calreticulin is dependent on
a castanospermine-sensitive interaction with another cofac-
tor such as tapasin. Figure 2 shows that the binding of cal-
reticulin, tapasin and TAP to MHC class I was cooperative.
Thus, the amount of HLA-A*0201 recovered from cells
with anti-calreticulin antiserum was drastically reduced
when either TAP (in T2 cells) or tapasin (in .220 cells)
were missing (Figure 2b). To date, it has not been possible
to look at the association between TAP, tapasin and HLA-
A*0201 in cells that lack calreticulin. It is possible,
however, to block the calreticulin–MHC class I interaction
with castanospermine. Figure 2c shows that the interaction
between HLA-A*0201 and TAP was sensitive to the inhi-
bition of glycan trimming by castanospermine. Like the
calreticulin–MHC class I interaction, there was a dose-
dependent effect of castanospermine on the TAP–MHC
class I interaction (Figure 2d). These experiments indicate
that the failure of T134K to interact with calreticulin
could be secondary to its failure to interact with other
cofactors in the loading complex. They also show that a
stable interaction between class I molecules and each
member of this complex is dependent on the presence of
the other component members.
T134K molecules are released into the secretory pathway
prematurely as peptide-receptive molecules [3]. They
escape degradation in the ER — which is the usual fate of
peptide-receptive class I molecules synthesised in cells in
which the supply of peptides to the ER is limited. If
T134K was bypassing the ‘peptide loading’ step of antigen
presentation, we would expect this rapid transport of
empty mutant molecules to be insensitive to the presence
of a functional TAP.
To test this, we introduced T134K into cell lines that are
unable to supply newly synthesised class I molecules with
TAP-derived peptides because of an absent or defective
TAP complex. In this case, only a TAP-independent
peptide pool would exist in the ER. In normal C1R cells,
around 70% of wild-type HLA-A*0201 leaves the ER
stably bound to peptides, whereas the remaining 30% of
molecules are not stabilised, and as a result remain in the
ER to be degraded [3]. In contrast, only a few (14%)
T134K molecules leave the ER stably bound to peptides;
the majority (70%) exit in a peptide-receptive state, with
very few molecules being retained in the ER [3]. The
intracellular fate of both T134K and normal HLA-A*0201
expressed in the TAP-defective cell line BM36.1 [9] was
then assessed for comparison. Figure 3 shows that in
BM36.1 cells, the majority of T134K molecules, like
HLA-A*0201, did not exit the ER but were retained as
unstable complexes that were sensitive to endoglycosidase
H (87% and 61% for T134K and HLA-A*0201, respec-
tively). Only about 10% of T134K molecules and 30% of
wild-type HLA-A*0201 molecules exited the ER in
BM36.1 cells as stable complexes. Thus, we show for the
first time that although a TAP-derived supply of peptides
to the ER is necessary to ensure the stable peptide-depen-
dent assembly of MHC class I molecules and the presen-
tation of endogenous antigens to cytotoxic T lymphocytes,
it is not sufficient. A supply of TAP-derived peptides is
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Figure 1
T134K interacts with calnexin (CX) but does
not associate with calreticulin (CRT).
(a) Metabolically labelled lysates of C1R
cells transfected with HLA-A*0201 (C1R-
A2.1) or T134K (C1R-T134K) were immuno-
precipitated with monoclonal antibodies
W6/32 (anti-HLA-A,B,C) and BB7.2 (anti-
HLA-A2) or with anti-calreticulin or anti-
TAP2 antisera. The immunoprecipitates were
analysed by one-dimensional isoelectric
focusing (1D-IEF) to resolve coprecipitating
HLA-A*0201 (A2.1) and HLA-Cw4. T134K
migrated higher than wild-type HLA-A*0201
in the 1D-IEF gel, due to the addition of
positive charge by the threonine-to-lysine
mutation. HLA-Cw4 was co-precipitated
equally well from lysates of either C1R-A2.1
or C1R-T134K cells, and served as an
internal control. (b) β2m-deficient Daudi
cells were infected with recombinant
vaccinia virus expressing either HLA-A*0201
or T134K. (Daudi cells were used because
calnexin has been shown to bind to free
class I heavy chain in the absence of β2m;
the association of HLA-A*0201 and T134K
with calnexin is therefore shown best in
β2m-deficient cells.) Infected cells were then
split in half; half were not treated and half
were treated with 600 µg/ml
castanospermine (CAST) at a concentration
known to prevent trimming of precursor
triglucosylated N-linked glycans Glc3 to the
monoglucosylated Glc1 form (this trimming
is required for calnexin to bind to class I
heavy chains). Metabolically labelled lysates
were then immunoprecipitated with either
anti-heavy chain (anti-HC) or anti-calnexin
(anti-CX) antisera. The top and bottom of the
1D-IEF gels are shown to save space.
(c) The interaction between HLA-A*0201
and calreticulin is carbohydrate dependent.
C1R-A2.1 cells were treated with an
increasing concentration of
castanospermine (0, 100, 300, 600 µg/ml).
Metabolically labelled HLA-A*0201
molecules were then immunoprecipitated
with BB7.2 antibody or coimmuno-
precipitated with anti-calreticulin antiserum.
The effectiveness of castanospermine was
indicated by the change in mobility of HLA-
A*0201 in the SDS polyacrylamide gel as
the dose of castanospermine increased,
corresponding to the inhibition of glucose
trimming from the triglucosyl Glc3 to
monoglucosyl Glc1 core glycan. Note that
only the fast mobility Glc1 is associated with
calreticulin. The band migrating just above
the Glc3 heavy chain band in the anti-
calreticulin precipitations is most probably
tapasin (data not shown).
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clearly essential to allow T134K molecules to escape
degradation and to exit the ER. They nevertheless enter
the secretory pathway in a peptide-receptive state when
assayed in vitro. This suggests that the mutation acts to
prevent class I molecules from optimising the binding of
their peptide ligand, rather than preventing peptide
binding per se. It is this failure to optimise the binding of
the peptide ligand that leads to the egress of unstable class
I molecules from the ER. 
The optimisation of peptide loading onto class I com-
plexes may be linked to their retention time in the ER.
We have investigated this proposal using the drug
brefeldin A (BFA), which promotes the retention of newly
synthesised glycoproteins in the ER by reorganising the
structure of the ER and Golgi apparatus. Figure 4 shows
that when C1R-T134K cells were incubated with BFA for
30 minutes (the approximate half-time for egress of wild-
type HLA-A*0201 molecules from the ER, compared with
12 minutes for T134K), the fraction of stable molecules
increased dramatically from 17% in the absence of BFA to
67% in its presence. This indicates that ER retention
alone may facilitate the assembly of class I molecules with
optimal peptides.
Mechanisms by which peptide optimisation could be
achieved include peptide exchange, or the enzymatic
trimming of suboptimal peptides to a suitable length for
class I binding [10,11]. In support of the peptide exchange
mechanism, Sijts and Pamer [12] have shown recently that
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The binding of calreticulin (CRT), tapasin and TAP to HLA-A*0201
(A2.1) is cooperative. (a) A schematic representation of the
multicomponent loading complex. Metabolically labelled lysates of
(b) normal .221-A2.1 cells, tapasin-deficient .220-A2.1 cells and TAP-
deficient T2 cells and of (c) C1R-A2.1 cells (mock-treated or treated
with 600 µg/ml castanospermine, CAST) were immunoprecipitated
with BB7.2 (anti-HLA-A2) antibody or with anti-TAP2 or anti-
calreticulin antisera. The immunoprecipitates were analysed by 1D-IEF
to resolve coprecipitating HLA-A*0201 and HLA-Cw4. Note that less
HLA-A*0201 associated with calreticulin when cells lacked either
tapasin (.220-A2.1) or TAP (T2). When the interaction between
calreticulin and HLA-A*0201 was disrupted with castanospermine (c),
less HLA-A*0201 coprecipitated with TAP. (d) Metabolically labelled
cell lysates of C1R-A2.1 cells treated with castanospermine at the
indicated concentrations were immunoprecipitated with BB7.2 (anti-
HLA-A2) antibody or with anti-TAP2 antiserum. Immunoprecipitates
were analysed by 10% SDS–PAGE. As the dose of castanospermine
increased, the amount of HLA-A*0201 associated with TAP
decreased. TAP associated only with the Glc1 form of HLA-A*0201.
Figure 3
BM36.1 cells were infected with recombinant vaccinia virus expressing
either HLA-A*0201 (A2.1) or T134K. Cells were metabolically labelled
and chased for the time periods indicated. BB7.2-reactive class I
complexes were then recovered from cell lysates after overnight pre-
clearing in the absence (– peptide) or presence (+ peptide) of a
saturating concentration (20 µM) of stabilising HIV pol peptide. Only
heavy-chain bands are shown because human β2m is poorly visualised
following a 10 min pulse-label. Intracellular maturation was determined
by the sensitivity of class I molecules to endoglycosidase H (EHS
indicates endoglycosidase-H-sensitive; EHR indicates
endoglycosidase-H-resistant). The intracellular fate of class I
complexes in each cell line could be quantified (see Supplementary
material): from each chase, the proportion of stable class I complexes
that exited the ER was 32% for HLA-A*0201 and 11% for T134K; the
proportion of ‘peptide-receptive’, unstable complexes that exited was
7% for HLA-A*0201 and 2% for T134K; the proportion of class I
molecules that remained in the ER was 61% for HLA-A*0201 and
87% for T134K. When C1R cells were infected with the recombinant
vaccinia viruses, both T134K and wild-type HLA-A*0201 exited the ER
and became endoglycosidase-H-resistant; this is also the case when
T134K and HLA-A*0201 are expressed from transfected genes [3].
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peptide dissociation from class I molecules in the ER is
enhanced compared with the cell surface and yet ER-resi-
dent class I molecules have a greater capacity to bind new
epitopes. This process might be a ‘facilitated exchange’
process, requiring the assistance of a separate cofactor
similar to the role of HLA-DM described for the class II
pathway (reviewed in [13]). As for MHC class II, there
might be varying degrees of dependency on such a cofac-
tor between alleles in order to bring about effective
peptide exchange [14–16]. 
Materials and methods
Cell lines, antibodies and peptides
The TAP-deficient .174 cells, tapasin-deficient .220 cells, and tapasin-
competent .221 cells, as well as .220-A2.1 and .221-A2.1 cells, were
the generous gifts of R. DeMars. BM28.7 [9] and TAP-defective
BM36.1 cells were a gift from A. Ziegler. T2 cells were a gift from P.
Cresswell. C1R cells transfected with HLA-A*0201 (C1R-A2.1) and
HLA-A*0201T134K (C1R-T134K) were a gift from J. Frelinger. Mono-
clonal antibodies used were anti-HLA-A2 (BB7.2 [17]) and anti-HLA-A,
anti-HLA-B and anti-HLA-C (W6/32 [18]). Rabbit anti-free-heavy-chain
and rabbit anti-TAP2 sera were generated by and were a gift from
J.J. Neefjes [3]. Rabbit anti-calreticulin was from Affinity Bioreagents.
The rabbit antiserum to calnexin was generated by B. Gao to a syn-
thetic peptide corresponding to the 15 carboxy-terminal residues of
human calnexin. The HLA-A*0201 binding peptides ILKEPVHGV (HIV
pol residues 476–484) and GILGFVFTL (influenza A MP58–66) were
synthesised by Research Genetics.
Pulse-chase analysis, immunoprecipitation,
coimmunoprecipitation and band analysis
These were performed exactly as described [3]. The fractions of a
pulse-labelled cohort of class I molecules which either leave the ER in
stable association with peptide, or leave the ER as unstable peptide-
receptive complexes, or are retained and degraded in the ER as
peptide-receptive complexes were calculated from the integrated
optical density (IOD) of endoglycosidase-H-sensitive and endogly-
cosidase-H-resistant class I heavy chain bands. For details see the
Supplementary material.
Viruses
Recombinant vaccinia viruses were made by homologous recombina-
tion into the thymidine kinase gene of WR vaccinia as described [11].
For immunoprecipitation experiments, cells were pelleted and infected
with recombinant vaccinia at multiplicity of infection (MOI) = 10 for
90 min at 37°C. Cells were then washed once and resuspended in
warm medium for 3.5 h prior to metabolic radiolabelling.
Supplementary material
Details of the quantitation of pulse-chase immunoprecipitation are pub-
lished with this paper on the internet.
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Figure 4
Retention in the ER promotes intracellular peptide loading of T134K.
Cells metabolically labelled for 5 min were incubated in the absence or
presence of 10 µM BFA before they were lysed. The number of sialic
acid residues present on the T134K molecules is labeled. T134K that
became stably assembled was calculated as a fraction of the total
cohort (visualised at t = 0 by the addition of stabilising peptide). Note
that T134K becomes di-sialylated only in the absence of BFA.
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S1
The quantitation of pulse-chase immunoprecipitation
Gels were fixed, stained (for SDS polyacrylamide gels), treated with
Amplify (Amersham), dried and visualised by autoradiography at
–80°C. Bands were quantitated using a MilliGen Bioimage Analyser
which expresses band intensities as an integrated optical density
(IOD). The fractions of a pulse-labelled cohort of class I molecules
which leave the ER in stable association with peptide (A), leave the ER
as unstable peptide-receptive complexes (B) or are retained and
degraded in the ER as peptide-receptive complexes (C) were calcu-
lated from the IOD of endoglycosidase-H-sensitive (EHS) and endogly-
cosidase-H-resistant (EHR) class I heavy chain bands precipitated by
conformation-specific antibodies in the presence or absence of
peptide. 
A = (maximum IOD EHR HC without peptide)/T (× 100%); 
B = [(maximum IOD EHR HC with peptide) — (maximum IOD EHR HC
without peptide)]/T (× 100%); 
C = [(maximum IOD EHS HC with peptide) — (maximum IOD EHR HC
with peptide)]/T (× 100%);
where T = maximum IOD (EHS HC + EHR HC) with peptide. All experi-
ments were performed at least twice and the reproducibility was found
to be good. Fractions A, B and C varied less than ±20% from day to
day and were not affected by minor differences in the total amount of
class I heavy chain synthesised following vaccinia delivery of the heavy
chain genes. The accuracy of the calculation was checked by ensuring
that the fraction C calculated above equalled the difference between
fractions A and B.
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